In 2024, the Food and Drug Administration approved 127 innovator and biosimilar drugs, marking a slight decrease from the previous year but showcasing significant advancements in the biotech sector. GlobalData’s report highlights key milestones, including the approval of the first biosimilar of Stelara, Wezlana, and the first denosumab biosimilars, Wyost and Jubbonti. These approvals are expected to enhance patient access to affordable treatments and drive up production volumes. Despite the decline in overall approvals, the year saw a surge in innovative drug approvals, especially from small pharmaceutical companies securing their first market approvals.
Read more from drugstorenews.com